All In Biotech

Free tool

FAERS Monitor: Sunharbo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 221291 or its brand name (Sunharbo, Asundexian). Reports on generic versions are filed under their own applications.

Reports

6

Serious

6

100% of reports

Hospitalization

5

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • upper gastrointestinal haemorrhage3
  • abdominal pain2
  • pancreatitis necrotising2
  • splenic vein thrombosis2
  • colon cancer1
  • duodenal ulcer haemorrhage1
  • lower gastrointestinal haemorrhage1
  • procedural complication1
  • procedural haemorrhage1

Reports by year received

View as table
YearReports
20231
20242
20253

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,153 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
splenic vein thrombosis213897.14467.015,570
pancreatitis necrotising23054.0984.23,430
duodenal ulcer haemorrhage11225.6204.7305
procedural haemorrhage1896.5149.8223
upper gastrointestinal haemorrhageSignal3625.3280.91,299
lower gastrointestinal haemorrhage1474.079.2118
procedural complication1457.376.4113
colon cancer1235.339.358
abdominal pain230.19.731

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.